GenVec
Public company | |
Traded as | NASDAQ: GNVC |
Industry | Pharmaceuticals |
Headquarters | Gaithersburg, Maryland, United States |
Key people | Douglas J. Swirsky, President and CEO |
Products | CGF166Clinical trial#Phase 1/2 |
Number of employees | 13 |
Website | www.genvec.com |
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.
References
This article is issued from Wikipedia - version of the Monday, January 04, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.